Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
Japan Pharmaceutical Manufacturers Association (JPMA) President Asuka Miyabashira on July 30 welcomed the government’s new honebuto policy as an important step toward strengthening incentives for pharmaceutical innovation but stressed that the next challenge will be translating that direction into concrete…
To read the full story
Related Article
- PhRMA Welcomes Honebuto, Prods Japan to Launch Reform This Year
July 22, 2026
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- JPMA Backs Honebuto 2026 Innovation Agenda
July 21, 2026
ORGANIZATION
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
- UA Zensen Manufacturing Wage Hikes at 4.89%, Pharma in Mid-4% Range
September 4, 2026
- LINK-J Eyes Stronger Ties with AI, Semiconductor Sectors
September 2, 2026
- JGA Unveils Industry Vision 2035, Eyes Sustainable Structure
September 2, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…